Key facts
- This page summarizes UBS Oncology Impact Fund L.P.'s Form 4 filing for Cullinan Oncology, Inc. (CGEM).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 20 Sep 2021, 17:31.
UBS Oncology Impact Fund L.P. - 16 Sep 2021 Form 4 Insider Report for Cullinan Oncology, Inc. (CGEM)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- CGEM
- Reported as of
- 16 Sep 2021
- Net transaction value
- -$90,783
- SEC form
- 4
- Accepted by SEC
- 20 Sep 2021, 17:31:24 UTC
- Prior SEC filing
- 16 Sep 2021
- Next SEC filing
- 05 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ansbert Gadicke, managing partner of BioImpact Capital LLC, the general partner of Oncology Impact Fund (Cayman) Management L.P., the general partner of UBS Oncology Impact Fund L.P
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
UBS Oncology Impact Fund L.P. filed Form 4 for Cullinan Oncology, Inc. (CGEM) on 20 Sep 2021.
Change
- Previous filing in this sequence was filed on 16 Sep 2021.
- Current net transaction value: -$90,783.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CGEM
transaction
Common Stock
Sale
- Transaction value
- $90,783
- Shares
- -3,124
- Change %
- -0.04%
- Price
- $29.06
- Shares after
- 7,648,268
- Date
- 16 Sep 2021
- Ownership
- Direct
- Footnotes
- F1, F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.14 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F3
These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC.
Footnote F4
Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.